Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants

NCT ID: NCT02935101

Last Updated: 2019-05-23

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-10-31
• Study Completion Date: 2017-05-31

Brief Summary

The purpose of this study is to evaluate whether prednisolone lowers intensity and frequency of craving in heroin-addicted subjects undertaking a detoxification of cocaine and/or heroin.

Detailed Description

Participants of this study are 120 heroin-addicted patients who are inward for a detoxification program for either cocaine or cocaine and heroin. Depending on the detoxification substance(s) there will be two groups of participants: Detoxification of cocaine (A; 60 participants) and detoxification of heroin and cocaine (B; 60 participants). The detoxification starts mandatory with the admission to the ward and lasts about 1-2 weeks. The participation in the study lasts about 4-5 weeks (including follow-up visits). Intake of study medication starts two days after admission and one day after informed consent. Each participant will get either 30mg/d prednisolon or placebo during five days. Participants will be under normal medical supervision during the treatment phase until follow-up 2 (final examination) provided by ward staff. Treatment days and follow-up 1 and 2 consist of : (1) vital signs (BP, HR, temperature) as measured in the daily routine, (2) at midday: visual analogue scales asking about craving for heroin and cocaine at the moment, (3) afternoon: questionnaires to survey mainly the withdrawal symptoms and vegetative parameters.

Conditions

Opioid Dependence; Cocaine Dependence

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

Prednisolon

Participants will receive an oral administration of prednisolone or placebo two times daily for the first five days of opioid detoxification, starting after one day of regular detoxification as baseline. Oral prednisolone will be administered in a dose consistent with standard treatment guidelines for glucocorticoid deficiency (Oelkers, 1996).

Group Type: EXPERIMENTAL

Prednisolone

Intervention Type: DRUG

formulated for oral administration. encapsulated.

Placebo

Identical looking capsules like the IMP containing placebo (without active component) for oral administration.

Group Type: PLACEBO_COMPARATOR

Placebo (for Prednisolone)

Intervention Type: DRUG

Sugar pill manufactured to mimic Prednisolon 10mg capsules

Interventions

Prednisolone

formulated for oral administration. encapsulated.

Intervention Type: DRUG

Placebo (for Prednisolone)

Sugar pill manufactured to mimic Prednisolon 10mg capsules

Intervention Type: DRUG

Other Intervention Names

Prednisolon Streuli(R)

Eligibility Criteria

Inclusion Criteria

• Informed Consent as documented by signature,
• age ≥18,

• Group A Detoxification of stimulants (cocaine, amphetamine and/or methamphetamine); ICD-10: F14.2 and/or F15.2) OR Stable opioid dependency (no parallel consumption). Detoxifica-tion of stimulants.
• Group B Opioid dependency and dependency of stimulants (cocaine, amphetamine and/or methamphetamine) and Detoxification of parallel consumption of stimulants and heroin (ICD-10: F11.2, 14.2, 15.2)
• admission for detoxification to ward U2 of the University Psychiatric Hospital of Basel

Exclusion Criteria

• contraindications to the class of drugs under study or to any of the excipients, e.g. known hypersensitivity or allergy to class of drugs or the investigational product;
• acute or severe co-morbid psychiatric disturbances (such as a heavy episode of major depression with suicidal ideations, acute exacerbation of a bipolar disorder, acute exacerbation of schizophrenia, alcohol addiction with an acute relapse, psychosis, dementia);
• current medical conditions excluding participation (such as acute infectious disease, moni-tored by elevated CRP, diabetes mellitus, anticoagulation therapy);
• recent history of systemic or topic glucocorticoid therapy;
• alcohol intake > 0.0 ‰ according to breathalyser test on day 0 (screening) to exclude severe alcohol abuse;
• specific drugs not allowed during the study or for specific periods of time prior to the administration of the test dose: Anticoagulant agents, antidiabetic agents, cyclosporine;
• women who are pregnant or breast feeding;
• intention to become pregnant during the course of the study;
• inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia;
• participation in another study with investigational drug within the 30 days preceding or during the present study;
• previous enrolment into the current study;
• enrolment of the investigator, his/her family members, employees and other dependent persons.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Psychiatric Hospital of the University of Basel

OTHER

Sponsor Role: collaborator

Prof. Dominique de Quervain, MD

OTHER

Sponsor Role: lead

Responsible Party

Prof. Dominique de Quervain, MD

Director Division Cognitive Neuroscience

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Antje Kemter, MD

Role: PRINCIPAL_INVESTIGATOR

UPK Basel

Locations

Psychiatric Hospital University of Basel

Basel, , Switzerland

Countries

Switzerland

Other Identifiers

2016-00851

Identifier Type: -

Identifier Source: org_study_id